Aarti Industries’ operational performance exceeded street expectations. Factors which supported this was return of discretionary demand to pre-COVID levels. Secondly, despite the serious second wave, the company was able to pass on the increase in cost to end client.
Company’s management is positive about 25 to 35 percent growth in topline in the current fiscal. This is backed by commercialisation of new capacities. The benefit of two long-term contracts are likely to kick-in from fiscal 2023 onwards.
Another trigger to watch is value unlocking in pharma business, wherein the company is waiting for regulatory approvals.
For the longer-term, management is focused on ambitious capex plan worth Rs 4,500 crore. Here, new projects in focus are downstream products.
In the special segment of ‘Moneycontrol Pro Ideas For Profit’, Moneycontrol.com’s Anubhav Sahu gets more details on the company’s performance, going forward.
Watch the video for more
Disclaimer: The views and investment tips expressed by investment experts on CNBCTV18.com are their own and not that of the website or its management. CNBCTV18.com advises users to check with certified experts before taking any investment decisions.